CompanyGraph
What stands out
- Dividend several times the last twelve months' earnings
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Dividend several times the last twelve months' earnings
Dividends view
Yield
1.72%
Annual Rate
CNY 0.70Paid annual
Payout Ratio
340.1%High
Payback Period
58.2 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.08BCNY904.28M · vs all stocks (USD)
Trailing P/E
193.33xvs Biotechnology peers
Revenue (TTM)
449.50MCNY66.85M · vs all stocks (USD)
Profit Margin
6.74%vs Biotechnology peers
Beta
0.6630xvs all stocks
52-Week Change
-0.42%vs all stocks
Market Capitalization
6.08BCNY904.28M · vs all stocks (USD)
Enterprise Value
4.30BCNY639.83M · vs all stocks (USD)
Trailing P/E
193.33xvs Biotechnology peers
Price to Sales (TTM)
13.49xvs Biotechnology peers
Price to Book (MRQ)
2.51xvs Biotechnology peers
Enterprise to Revenue
9.57xvs Biotechnology peers
Enterprise to EBITDA
134.57xvs Biotechnology peers
Gross Margin
47.56%vs Biotechnology peers
Profit Margin
6.74%vs Biotechnology peers
Operating Margin
-4.99%vs Biotechnology peers
Return on Assets (TTM)
0.18%vs Biotechnology peers
Return on Equity (TTM)
1.21%vs Biotechnology peers
Revenue (TTM)
449.50MCNY66.85M · vs all stocks (USD)
Revenue per Share (TTM)
3.10CNYUpdated Aug 21, 2026Quarterly Revenue Growth
1.70%vs Biotechnology peers
Gross Profit (TTM)
202.39MCNY30.10M · vs all stocks (USD)
EBITDA (TTM)
65.12MCNY9.68M · vs all stocks (USD)
Net Income (TTM)
30.31MCNY4.51M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-47.62%vs Biotechnology peers
Operating Cash Flow (TTM)
60.91MCNY9.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-83.81MCNY-12.46M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.7000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.72%vs all stocks
Payout Ratio
340.14%vs Biotechnology peers
Minority Interest (Equity)
1.47MCNYFY2025 · Dec 31, 2025Revenue
448.01MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
241.78MCNYFY2025 · Dec 31, 2025Gross Profit
206.23MCNYFY2025 · Dec 31, 2025Operating Income
35.89MCNY5.34M · vs all stocks (USD)
Pre-tax Income
49.68MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.55MCNYFY2025 · Dec 31, 2025Net Income
47.13MCNYFY2025 · Dec 31, 2025EBIT
35.89MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
65.12MCNYFY2025 · Dec 31, 2025Research & Development
83.48MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
44.92MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.38MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
38.27MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
144.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
144.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
47.13MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.13MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
63.54MCNYFY2025 · Dec 31, 2025Free Cash Flow
-63.59MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.17BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
47.13MCNYFY2025 · Dec 31, 2025Other Non-cash Items
12.98MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
3.79MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-345.74KCNYFY2025 · Dec 31, 2025Capital Expenditures
-127.13MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.22BCNYFY2025 · Dec 31, 2025Sale of Investments
5.48BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
131.70MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-159.88MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.82MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-158.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
149.33MSharesUpdated Aug 21, 2026Float Shares
56.58MSharesUpdated Aug 21, 2026% Held by Insiders
63.27%vs all stocks
% Held by Institutions
5.75%vs all stocks
Total Cash (MRQ)
1.40BCNY208.72M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.63CNYUpdated Aug 21, 2026Total Debt (MRQ)
435.36KCNY64.74K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0002xvs Biotechnology peers
Current Ratio (MRQ)
14.11xvs Biotechnology peers
Book Value per Share (MRQ)
16.19CNYUpdated Aug 21, 2026Total Assets
2.54BCNY377.64M · vs all stocks (USD)
Total Current Assets
1.66BCNYFY2025 · Dec 31, 2025Total Liabilities
168.17MCNYFY2025 · Dec 31, 2025Total Non-current Assets
877.94MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
10.19MCNYFY2025 · Dec 31, 2025Total Current Liabilities
157.98MCNYFY2025 · Dec 31, 2025Cash
1.48BCNYFY2025 · Dec 31, 2025Cash Equivalents
205.50KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.48BCNYFY2025 · Dec 31, 2025Other Short-term Investments
13.76MCNYFY2025 · Dec 31, 2025Accounts Receivable
89.37MCNYFY2025 · Dec 31, 2025Inventory
69.68MCNYFY2025 · Dec 31, 2025Accounts Payable
98.67MCNYFY2025 · Dec 31, 2025Short-term Debt
488.32KCNYFY2025 · Dec 31, 2025Other Current Liabilities
107.30KCNYFY2025 · Dec 31, 2025Common Stock (Book)
149.33MCNYFY2025 · Dec 31, 2025Retained Earnings
1.43BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.37BCNY352.63M · vs all stocks (USD)
Treasury Stock
18.07MCNYFY2025 · Dec 31, 202552-Week Low
30.40CNYUpdated Aug 21, 202652-Week High
50.98CNYUpdated Aug 21, 202652-Week Change
-0.42%vs all stocks
Beta
0.6630xvs all stocks
50-Day MA
37.02CNYUpdated Aug 21, 2026200-Day MA
37.80CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.56MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.53MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.2100CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Structural Tensions
Dividend several times the last twelve months' earningsSignificant
Payout Ratio: 3.40Dividend per Share: 0.70Earnings per Share: 0.21
High gross margins eroded by operating costsNotable
Gross Margin: 0.48Profit Margin: 0.07
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
LB Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
L&C Bio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
FP Holdings, Inc.
3 interpretationsRetained Earnings Heavy With Elevated PayoutCash Elevated Relative to Current Liabilities and Total AssetsHigh Retained Earnings With Profitability And Equity
Oriental Watch Holdings Limited
3 interpretationsRetained Earnings Heavy With Elevated PayoutCash Elevated Relative to Current Liabilities and Total AssetsHigh Retained Earnings With Profitability And Equity
Liaoning Chengda Biotechnology Co., Ltd.
3 interpretationsRetained Earnings Heavy With Elevated PayoutCash Elevated Relative to Current Liabilities and Total AssetsHigh Retained Earnings With Profitability And Equity